Willingness to return to enrolling institution for follow-up during the active monitoring phase (that is, the active treatment and observation portion) of the study); patients who have been formally transferred to another active and approved site participating in this study would not need to return to the enrolling institution for this purpose
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Willingness to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)\r\n* Note: during the Active Monitoring Phase of a study (i.e., active treatment and observation), participants must be willing to return to the consenting institution for follow-up
Willing to return to the enrolling institution for follow-up (during the Active Monitoring Phase of the study); Note: during the Active Monitoring Phase of a study (i.e., active treatment and observation), participants must be willing to return to the consenting institution for follow-up
Willing to return to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)
Willing to return to the enrolling institution for follow-up (during active treatment and active monitoring phase of the study)
Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)
Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Willing to return to enrolling institution for follow-up during active monitoring phase of the study
Willing to return to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)\r\n* Note: During the active monitoring phase of a study (i.e., active treatment and observation), participants must be willing to return to the consenting institution for follow-up
Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study); Note: during the Active Monitoring Phase of a study (i.e., active treatment and observation), participants must be willing to return to the consenting institution for follow-up
Willing to return to enrolling institution for follow-up during the Active Monitoring phase of the study\r\n* Note: the Active Monitoring phase of a study includes active treatment and observation
Willing to return to the enrolling institution for follow-up (during active treatment and active monitoring phase of the study)
Patient is willing to undergo treatment and monitoring at the enrolling institution
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)\r\n* Note: During the active monitoring phase of a study (i.e., active treatment and observation), participants must be willing to return to the consenting institution for follow-up
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study [i.e. active treatment and observation])
Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)
Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)\r\n* Note: during the Active Monitoring Phase of a study (i.e., active treatment and observation), participants must be willing to return to the consenting institution for follow-up
Willingness to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)\r\n* Note: During the active monitoring phase of a study (i.e., active treatment and observation), participants must be willing to return to the consenting institution for follow-up
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)\r\n* Note: during the active monitoring phase of a study (i.e., active treatment and observation), participants must be willing to return to the consenting institution for follow-up
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Willing to return to enrolling institution for follow-up (active monitoring phase of the study); Note: During the active monitoring phase of a study (i.e., active treatment), participants must be willing to return to the consenting institution for follow-up
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Willingness to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Willing and able to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study); Note: During the Active Monitoring Phase of a study (i.e., active treatment and observation), participants must be willing and able to return to the consenting institution for follow-up
Willingness to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Willing to return to consenting institution for follow-up (during the active monitoring phase of the study)
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study); Note: during the Active Monitoring Phase of a study (i.e., active treatment and observation), participants must be willing to return to the consenting institution for follow-up
Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Willingness to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Willing to return to consenting Mayo Clinic institution for follow-up during the Active Monitoring Phase of the study; Note: during the Active Monitoring Phase of a study (i.e., active treatment and observation), participants must be willing to return to the consenting institution for follow-up
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)
Willingness to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)\r\n* Note: during the active monitoring phase of a study (i.e., active treatment and observation), participants must be willing to return to the consenting institution for follow-up
Willing to return to an Academic and Community Cancer Research United (ACCRU) enrolling institution for follow-up (i.e., active monitoring, which includes active treatment and observation)
Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)
Willing to work with the enrolling institution for follow-up (during the active monitoring phase of the study)
Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)\r\n* Note: During the Active Monitoring Phase of a study (i.e., active treatment and observation), participants must be willing to return to the consenting institution for follow-up
Willing to return to enrolling institution for follow-up during the Active Monitoring Phase (the active treatment and observation portions) of the study; patients are encouraged to return to the enrolling institution; however, patients may receive radiation therapy at a different institution other than the enrolling institution
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)\r\n* Note: During the active monitoring phase of a study (i.e., active treatment and observation), participants must be willing to return to the consenting institution for follow-up
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)\r\n* Note: during the active monitoring phase of a study (i.e., active treatment and observation), participants must be willing to return to the consenting institution for follow-up
Willingness to return to Mayo Clinic for follow-up (during the active monitoring phase of the study)
Willing to return to enrolling institution for follow-up or have a local physician willing to submit response and outcome data; Note: any and all therapy, potentially in its entirety, may be conducted outside of the Mayo Clinic
Must be willing to return to Mayo Clinic enrolling institution for follow-up.
Rochester and Arizona patients: Willing to sign consent onto the Mayo Clinic Radiotherapy Patient Outcomes Registry and Biobanking study, IRB number 15-000136
Willingness to return to Mayo Clinic Rochester or another participating institution for follow-up; patients who are randomized to Arm B (cytotoxic chemotherapy) may receive chemotherapy at any oncology clinic able to provide the protocol-directed therapy and willing to send laboratory data to the participating institution; however, patients must be willing to return to the participating institution every two months for evaluation; patients who are randomized to Arm A must be willing to receive all treatment and follow-up at a participating institution
Planned radiation treatments at Mayo Clinic Rochester
Willing to undergo craniotomy and resection of their glioblastoma at Mayo Clinic
Willingness to return to Mayo Clinic in Rochester, Minnesota for follow-up
Willingness to return to Mayo Clinic in Rochester, Minnesota for follow-up
Central pathology review to determine evaluability of archived esophagogastroduodenoscopy (EGD)/biopsy sample\r\n* NOTE: If archived sample was collected > 8 weeks prior to pre-registration (reg), is not available in a timely manner, or was collected outside of Mayo Clinic and considered unevaluable, then baseline EGD with primary tumor biopsy at Mayo Clinic must be performed unless clinically contraindicated; patient is allowed to enroll regardless of whether this Mayo Clinic tissue sample is evaluable; (only 1 EGD with primary tumor biopsy performed at Mayo Clinic =< 8 weeks prior to pre-reg is required)\r\n* NOTE: For both archival or newly obtained tissue, only biopsies are adequate (fine needle aspiration [FNA] is not adequate)
Willingness to return to Mayo Clinic Rochester for follow-up
Willing to return to Mayo Clinic for follow-up
Willingness to return to the Mayo Clinic enrolling institution for follow-up
Willing to return to Mayo Clinic Rochester for follow-up
Willing to return to Mayo Clinic enrolling institution for follow-up
Willing to return to Mayo Clinic enrolling institution for follow-up
Willing to return to Mayo Clinic in Rochester, Minnesota for follow-up
Willingness to return to Mayo Clinic enrolling institution for follow-up
ARM A: Willingness to return to Mayo Clinic in Arizona for follow-up
ARM B: Willingness to return to Mayo Clinic in Arizona for follow-up
Willingness to return to Mayo Clinic Rochester for follow up
Willing to return to Mayo clinic for follow up
Willing to return to Mayo Clinic for follow up
Willing to return to Mayo Clinic for follow up
Date of Mayo Clinic Genomics Tumor Board review =< 3 months prior to registration
Willingness to return to Mayo Clinic Rochester for follow-up
Willing to return to consenting Mayo Clinic (Mayo Clinic’s campus in Rochester), for follow-up during the Active Monitoring Phase of the study
Rochester and Arizona patients: Willing to sign consent onto the Mayo Clinic Radiotherapy Patient Outcomes Registry and Biobanking study and collect involved blood specimen prior to the start of radiation therapy, IRB number 15-000136.
Willingness to return to Mayo Clinic Rochester for follow-up
Willingness to return to Mayo Clinic Rochester for follow-up appointments
Willing to return to Mayo Clinic Rochester for follow-up
Willing to return to Mayo Clinic Rochester, Mayo Clinic Arizona, Mayo Clinic Florida for treatment\r\n* Note: During the active monitoring phase of a study (i.e., active treatment and observation), participants must be willing to return to the consenting institution for follow-up
Willing to return to consenting Mayo Clinic (Mayo Clinic’s campus in Rochester, Mayo Clinic’s campus in Arizona, or Mayo Clinic’s campus in Florida) institution for follow-up during the active monitoring phase of the study
Willingness to return to Mayo Clinic Rochester for follow-up, except for some appointments that can be made with the local physician
Willingness to return to Mayo Clinic
Ability to provide informed consent, and to return to clinic for adequate follow-up for the period that the protocol requires
Willingness to return to Mayo Clinic Rochester for follow-up
Willing to receive their standard multimodality therapy at Mayo Clinic, Rochester
Willing to return to Mayo Clinic, Rochester during the observation phase
Willingness to return to Mayo Clinic for follow up
Willing to return to Mayo Clinic enrolling institution for follow-up
Willing to return to enrolling institution (Mayo Clinic in Arizona) for follow-up and all study treatments
Computed tomography (CT) simulation, immobilization, MRI and PET imaging, treatment planning, and all follow-up MRI and PET scans to be performed at Mayo Clinic Rochester; Note: the actual radiation therapy treatments and follow-up other than imaging can be performed at Mayo Clinic Rochester, Northfield, LaCrosse, Mankato, Eau Claire, or Albert Lea
Able to deliver four fresh (within 24 hours) stool samples to Mayo Clinic Rochester over a four month period
Willing to return to enrolling medical site for all study assessments
Willingness to return to enrolling institution for follow-up
Willing to return to enrolling institution for follow-up
Willing to return to enrolling institution for follow-up for a minimum of 1 year
Willing to return to enrolling institution for follow-up during the active treatment; event monitoring following completion of therapy may occur outside the enrolling institution
Willing to return to enrolling institution for follow-up
Willing to return to enrolling institution for follow-up
Willingness to return to the enrolling medical site for all study assessments
Willing to return to enrolling institution for follow-up
Willingness to return to enrolling institution for follow-up
Willing to return to enrolling institution for follow-up (during the treatment and observation phases of the study)
Willing to return to enrolling institution for follow-up
Willingness to return to enrolling institution for follow up
Willing to return to enrolling institution for follow-up 2-4 weeks after treatment discontinuation
Willing to return to participating medical institutions for follow-up
Willing to return to enrolling institution for follow-up
Willing to return to Academic and Community Cancer Research United (ACCRU) enrolling institution for follow-up
Willingness to return to a lymphoma Specialized Program of Research Excellence (SPORE) enrolling institution for follow-up
Willing to return to consenting institution for follow-up during the study
Willing to return to enrolling institution for follow-up
Willing to return to Alliance enrolling institution for follow-up
Willingness to return to the Alliance enrolling institution for follow-up
After the week-long study treatment, participants must be willing to return to the enrolling institution for a follow-up visit
Willing to return to enrolling institution for follow-up of the study and optional crossover (if applicable)
Willing to return to an Alliance enrolling institution for follow-up
Willingness to return to the enrolling institution for follow-up
Willing to undergo monthly follow-up assessment, either in person at the enrolling institution or by telephone
Willingness to return to the enrolling site for the study surgical procedures, including pre-operative and post-operative care; (patients in the ISDO arm must be willing to return to the enrolling site for yearly ovarian cancer assessment)
Willingness to return to the enrolling site for any surgical procedures including pre-operative and post-operative care
Willingness to return to the enrolling site for ovarian cancer screening during the study period
